Sellas Life Sciences Group, Inc. reported results
SEC 8-KRead source ↗
Sellas Life Sciences Group, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds138 adding, 49 cuttingOf 29 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 11% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Sellas Life Sciences Group, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 109% and a beta of 2.1 against the S&P 500.
- Heavily shorted. 26.7% of the shares available to trade are sold short (10.3 days of average volume to cover).
Latest results
- Earnings per share
- -$0.05 against an average estimate of -$0.04: missed by 11.1%
- Share reaction
- +6.6% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
- Next report
- November 11, 2026; average EPS estimate -$0.05
Price chart
- 1 day-11.7%
- 1 week-24.6%
- 1 month-27.2%
- This year+126.8%
- 1 year+369.8%
- 5 years-7.0%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 11, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
- Results
Sellas Life Sciences Group, Inc. reported results; disclosed a material event
SEC 8-KRead source ↗
No model value for Sellas Life Sciences Group, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Sellas Life Sciences Group, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Sellas Life Sciences Group, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 11, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.05 (range −$0.05 to −$0.05) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.20 | +20% | — | 0% |
| Next | −$0.10 | +50% | $53m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −4.8% on 90 days ago. In the last 30 days, 0 analysts raised Sellas Life Sciences Group, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.21 | −$0.15 |
| 60 days ago | −$0.21 | −$0.15 |
| 30 days ago | −$0.21 | −$0.13 |
| 7 days ago | −$0.21 | −$0.13 |
| Now | −$0.20 | −$0.10 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.04 | −$0.05 | −11.1% |
| Dec 2025 | −$0.06 | −$0.05 | +21.0% |
| Sept 2025 | −$0.08 | −$0.06 | +21.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 26.7% of tradable shares
- Days to cover
- 10.31 at average volume
- Short interest, 1 month
- −9% to October 15, 2026
- Held by institutions
- 37% of shares
- Held by insiders
- 0.9% of shares
- Employees
- 13 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| SLS | −5% | −57% | −55% | −2% | +263% | +127% |
| Industry peers (median) | −36% | −56% | −17% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| SLS | 42% | 50% | 50% | 33% | 58% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| SLS | −61% | −75% | −77% | −52% | −37% | −45% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from June 20, 2016 to January 18, 2024. Getting back needed a 13352841% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $1.39 – $15.46
- From 52-week high
- −44.7%
- vs 50-day average
- −28.9%
- vs 200-day average
- −0.5%
- Volatility (1 year)
- 109%
- Beta vs S&P 500
- 2.14
Share price after results
- Next day
- 5 up, 7 down typical move ±6.8%
- After a week
- 7 up, 5 down typical move ±11.1%
- After a month
- 10 up, 2 down typical move ±18.8%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 11, 2026 | +6.6% | −0.1% | +18.7% | +22.2% |
| July 27, 2026 | −10.9% | +0.3% | −0.9% | +24.5% |
| May 12, 2026 | +24.4% | +0.4% | +44.6% | +47.6% |
| March 19, 2026 | −3.8% | −1.7% | 0.0% | +0.8% |
| January 8, 2026 | −14.4% | +0.7% | −5.0% | −5.7% |
| November 12, 2025 | −3.3% | −1.6% | +0.7% | +34.4% |
| August 12, 2025 | +0.6% | +1.4% | +10.4% | +22.7% |
| May 13, 2025 | −1.9% | +0.8% | +26.0% | +7.1% |
| March 20, 2025 | −0.8% | −0.3% | −4.1% | +6.6% |
| November 13, 2024 | −5.9% | −0.6% | −8.1% | −35.6% |
| August 13, 2024 | +1.7% | +2.0% | +11.0% | +12.7% |
| May 14, 2024 | +7.3% | +1.7% | +3.6% | +5.8% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $1.1B
- Institutions reporting
- 191
- Shares held vs prior quarter
- ▲ 36.8%
- Positions opened / closed
- 60 / 25
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $222M | 15.1M | 20.6% | ▲ 23.5% |
| State Street Corp | $192M | 13.0M | 17.8% | ▲ 54.8% |
| Vanguard Capital Management LLC | $121M | 8.2M | 11.2% | ▲ 9.3% |
| Geode Capital Management, LLC | $72.1M | 4.9M | 6.7% | ▲ 24.8% |
| Anson Funds Management LP | $66.4M | 4.5M | 6.2% | New |
| Vanguard Portfolio Management LLC | $31.9M | 2.2M | 3.0% | ▲ 47.7% |
| Susquehanna International Group, LLP | $30.3M | 2.1M | 2.8% | ▲ 416.5% |
| Jones Financial Companies LLLP | $28.6M | 2.3M | 2.6% | ▲ 37.6% |
| Northern Trust Corp | $23.9M | 1.6M | 2.2% | ▲ 27.0% |
| Vanguard Fiduciary Trust Co | $19.7M | 1.3M | 1.8% | ▲ 11.0% |
| UBS Group AG | $18.5M | 1.3M | 1.7% | ▲ 68.1% |
| Morgan Stanley | $18.2M | 1.2M | 1.7% | ▼ 7.5% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Sellas Life Sciences Group, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $100,806 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $100,806 net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Kalin Katherine Bach Director | November 19, 2025 | Buy | 63,400 | $1.59 | $100,806 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- August 11, 2026
- July 27, 2026
- May 12, 2026
- March 19, 2026
- January 8, 2026
- November 12, 2025
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Sellas Life Sciences Group, Inc. in brief
- What does Sellas Life Sciences Group, Inc. do?
- Sellas Life Sciences Group, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Sellas Life Sciences Group, Inc.'s stock ticker?
- Sellas Life Sciences Group, Inc. trades under the ticker SLS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Sellas Life Sciences Group, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., State Street Corp and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Sellas Life Sciences Group, Inc. stock?
- Over the last 12 months, Sellas Life Sciences Group, Inc.'s directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
- When is Sellas Life Sciences Group, Inc.'s next earnings date?
- Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Sellas Life Sciences Group, Inc. announces its own schedule.
Follow research on Sellas Life Sciences Group, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.